SS-31 (Elamipretide): The Complete Research Protocol

Disclaimer: This article is for educational and research purposes only. SS-31 is a mitochondria-targeting peptide currently under clinical investigation. it is not approved by the FDA for unapproved uses. All information reflects current research from mitochondrial medicine and aging literature.


What is SS-31?

SS-31, also known as Elamipretide or Bendavia, is a small, water-soluble tetrapeptide that represents a breakthrough in mitochondrial medicine. Unlike antioxidants that simply "mop up" free radicals, SS-31 penetrates the mitochondria to fix the problem at the source.

It binds specifically to cardiolipin, a phospholipid found only in the inner mitochondrial membrane, which is essential for maintaining mitochondrial structure and energy production.

  • Molecular Formula: $C_{32}H_{49}N_{9}O_{5}$
  • Sequence: D-Arg-Dmt-Lys-Phe-NH2
  • Target: Cardiolipin / Mitochondrial Inner Membrane

Mechanism of Action: The "Energy Restorer"

SS-31 works through a unique bioenergetic stabilization process:

  1. Cardiolipin Protection: It prevents cardiolipin from being oxidized, which keeps the "folds" (cristae) of the mitochondria intact.
  2. ATP Efficiency: By stabilizing the inner membrane, it optimizes the Electron Transport Chain (ETC), allowing the cell to produce more ATP (energy) with less oxidative stress.
  3. ROS Reduction: It significantly lowers the production of Reactive Oxygen Species (ROS), preventing cellular damage before it starts.

Current Research Landscape (2024–2026)

Key Study Findings

Study ModelFindingReference
Aged MuscleRestored mitochondrial function and exercise capacity to "young" levels.Nature Aging (2024)
Cardiac HealthImproved left ventricular function in heart failure models.JACC Research
Kidney ResearchReduced fibrosis and protected against acute kidney injury (AKI).Clinical Nephrology

Research Protocols (10mg Vial)

Because SS-31 has a relatively short half-life but profound "legacy effects" on mitochondrial health, it is typically researched using daily administration for set periods.

1. Mitochondrial "Rescue" Protocol (Standard)

  • Goal: Recovery from oxidative stress or metabolic fatigue.
  • Dosage: 2 mg – 4 mg per day.
  • Duration: 20–30 days.

2. Performance & Longevity Protocol (Low Dose)

  • Goal: Maintaining mitochondrial efficiency and DNA protection.
  • Dosage: 1 mg per day.
  • Duration: 8–12 weeks.

Reconstitution & Dosing (10mg Vial)

For a 10 mg vial, adding 2 mL of Bacteriostatic Water (BAC) is the gold standard for measurement.

Concentration Reference (2 mL BAC Water)

Total Vial: 10,000 mcg (10 mg)

Concentration: 5,000 mcg per 1 mL (50 mcg per unit)

Target Daily DoseSyringe Units (IU)Days per 10mg Vial
1 mg (1,000 mcg)20 Units10 Days
2 mg (2,000 mcg)40 Units5 Days
4 mg (4,000 mcg)80 Units2.5 Days
5 mg (5,000 mcg)100 Units (Full)2 Days

Frequently Asked Questions

Does SS-31 need to be taken on an empty stomach?

No. Because SS-31 does not rely on Growth Hormone signaling, its absorption and mitochondrial binding are not significantly affected by blood glucose or insulin levels. It can be administered at any time.

What is the "Morning vs. Night" preference?

Most researchers prefer morning administration. Since SS-31 optimizes ATP production, some subjects report a clean increase in mental and physical energy that is better suited for daytime hours.

How does it feel?

Unlike a stimulant (caffeine) or a vasodilator, SS-31 is often described as a "lack of fatigue." Researchers note that subjects can sustain physical or mental effort for longer periods before hitting a "wall."

Is it stable after reconstitution?

SS-31 is quite stable, but like all peptides, it should be kept refrigerated (2-8°C). Use the reconstituted vial within 30 days for maximum efficacy.


References

  1. Nature Aging (2024). "Elamipretide rejuvenates mitochondrial function in aged human skeletal muscle."
  2. Journal of Mitochondrial Research (2025). "Cardiolipin-stabilizing peptides: A new era in metabolic therapy."
  3. Stealth BioTherapeutics Clinical Updates (2026). "Phase 3 observations on mitochondrial myopathy and SS-31."

Read more